Insmed
INSM

$71.04

2.56%

Market Cap: $12.2B

About: Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Employees: 912

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 16 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

350% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 27 (+21) [Q2]

242% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 38

190% more capital invested

Capital invested by funds: $4.05B [Q1] → $11.7B (+$7.68B) [Q2]

33% more funds holding

Funds holding: 283 [Q1] → 375 (+92) [Q2]

30% more repeat investments, than reductions

Existing positions increased: 130 | Existing positions reduced: 100

8.05% more ownership

Funds ownership: 100.6% [Q1] → 108.65% (+8.05%) [Q2]

2% less call options, than puts

Call options by funds: $458M | Put options by funds: $469M

See Fund Rankings

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$70

1%

downside

Avg. target

$86

21%

upside

High target

$102

44%

upside

16 analyst ratings

16 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target	27%upside $90	Buy Reiterated	29 Aug 2024
Truist Securities Nicole Germino 100% 1-year accuracy 6 / 6 met price target	20%upside $85	Buy Maintained	12 Aug 2024
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target	27%upside $90	Buy Reiterated	12 Aug 2024
TD Cowen Ritu Baral 50% 1-year accuracy 3 / 6 met price target	38%upside $98	Buy Maintained	9 Aug 2024
UBS Trung Huynh 100% 1-year accuracy 4 / 4 met price target	18%upside $84	Buy Maintained	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about INSM published over the past 30 days

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pending regulatory approval in Q4 2024. Insmed's R&D expenses were $146.7 million in Q2 2024, down from the previous year due to prior non-cash acquisition costs.

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Zacks Investment Research

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Investors Business Daily

Meta Stock Leads 5 Names Near Buy Points As Market Bounces

Meta leads five stocks near buy points as the market rallied Friday on Fed Chair Jerome Powell's speech.

Meta Stock Leads 5 Names Near Buy Points As Market Bounces

Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript

Insmed Incorporated (NASDAQ:INSM ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Jessica Fye – JPMorgan Ritu Baral – TD Cowen Joseph Schwartz – Leerink Partners Cameron Bozdog – Bank of America Jennifer Kim – Cantor Fitzgerald Leon Wang – Barclays Vamil Divan – Guggenheim Securities Liisa Bayko – Evercore ISI Graig Suvannavejh – Mizuho Nicole Germino – Truist Securities Andrea Tan – Goldman Sachs Operator Thank you for standing by. My name is John, and I will be your conference operator for today.

Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Zacks Investment Research

Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection Agreed Upon with U.S. FDA— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Aug. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 97 new employees.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

See News Rankings